LTB 4 as vaccine adjuvant

Details LTB 4 as vaccine adjuvant LTB 4 as vaccine adjuvant

2011-03-29

2011-03-29

Peng, Bo (Department: 1648)

Drug, bio-affecting and body treating compositions

Nonspecific immunoeffector, per se ; or nonspecific...

C514S560000, C560S128000

Reexamination Certificate

active

07914800

ABSTRACT:
The present invention relates to a vaccine adjuvant for enhancing immune response of an individual to a vaccine, which comprises an immune-enhancing effective amount of an LTB4 agent in association with a pharmaceutically effective vaccine carrier.

REFERENCES:
patent: 5919480 (1999-07-01), Kedar et al.
patent: 6093741 (2000-07-01), Gosselin et al.
patent: WO 97/29751 (1997-08-01), None
Yamaoka et al. Leukotriene B4 enhances activation, proliferation, and differentiation of human B lymphocytes. Journal of Immunology. Sep. 15, 1989, vol. 143, No. 6, 1996-2000.
K. A. Yamaoka et al., “Leukotriene B-4 Enhances Activation Proliferation and Differentiation of Human B Lymphocytes” Journal of Immunology, vol. 143, No. 6 (1989) p. 1996-2000, XP002210600.
S. Yamamoto et al. “Intraperitoneal administration of leukotriene B-4 (LTB-4) and omega-guanidino captoic acid methanesulfonate (GCA) increased the survival of mice challenged with methicillin-resistant staphylococcus aureus (MRSA).” Prostaglandins, vol. 45, No. 6 (1993) pp. 527-534 XP002210601.
H. Claesson et al. “Leukotriene B-4 in the Immune System” International Journal of Immunopharmacology, vol. 14, No. 3 (1992) pp. 441-449, XP002210602.
L. Gagnon et al., “Augmentation of Human Natural Cytotoxic Cell Activity by Leukotriene B4 mediated by enhanced effector-target cell binding and increased lytic efficiency” Cellular Immunology, Academic Press, vol. 110, No. 2, Dec. 1, 1987 pp. 243-252, XP000673615.
M. Rola-Pleszczynski et al., “LEukotriene B4 Augments Human Natural Cytotoxic Cell Activity” Biochemical and Biophysical Research Communications, Academic Press, San Diego, CA, US, vol. 113, No. 2 Jun. 15, 1983 pp. 531-537, XP000673613.
International Search Repprt dated Sep. 5, 2002.

Affiliated with

Also associated with

Rating

LTB 4 as vaccine adjuvant does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with LTB 4 as vaccine adjuvant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and LTB 4 as vaccine adjuvant will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2628010